TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04974944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study: NCT06463041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental, comparator and control
Description: How does implementing a GetUp Assist device in addition to a daily low-intensity functional or traditional training program affect Norwegian female office workers' physical health after 12 weeks?
Study: NCT06304194

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological samples
Description: The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS
Study: NCT06175091

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alarm management left to the discretion of the nurse
Description: alarm management left to the discretion of the nurse in charge of the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: restrictive alarm use strategy
Description: more restrictive protocol for the use of alarms
Study: NCT05870020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire (DBS-QoLs)
Description: The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion
Study: NCT05519410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and Lenvatinib
Description: Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC-FOLFOX
Description: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
Study: NCT05311618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM438
Description: NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM438
Description: NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM438
Description: NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA ®)
Description: Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA ®)
Description: Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
Study: NCT06320002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Intervention for fecal ostomy surgery
Description: This is a educational video-based supportive intervention to address practical skills and adaptation to life with a fecal ostomy
Study: NCT06039280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetylcysteine
Description: NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered in the same way as the drug in the experimental group.
Study: NCT05578326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: 240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: 3.2 mg/m2, over 60 minutes at day 1 of each cycle
Study: NCT05786820

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pycnogenol
Description: daily consumption of a pycnogenol-containing capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of a placebo capsule
Study: NCT05228288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional direct laryngoscopy (CDL)
Description: This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)
Description: This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video assisted laryngoscopy with hyper-angulated blade (H-VAL)
Description: The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
Study: NCT05182489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Adaptix™ titanium implants
Description: Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CAPSTONE® PEEK cage
Description: Medtronic CAPSTONE® PEEK cage
Study: NCT06031181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublobar Resection
Description: Sublobar Resection includes segmentectomy and wedge resection
Study: NCT05458869

Intervention type: PROCEDURE
Intervention: HPV Self-Collection
Description: Use HPV self-collection kit

Intervention type: OTHER
Intervention: Interview
Description: Attend interview

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05450224

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VVC-delivered Massed Imaginal Exposure
Description: Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
Study: NCT06517069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
Study: NCT05446038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Guided Self-Help FBT
Description: Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
Study: NCT05965869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes program
Description: CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
Study: NCT06426563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation treatment of thyroid nodule
Description: Use Radiofrequency or Microwave ablation device to treat thyroid nodule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation treatment of thyroid nodule
Description: Use Radiofrequency or Microwave ablation device to treat thyroid nodule
Study: NCT05290402

Intervention type: OTHER
Intervention: JEEVA (new digital health navigator app)
Description: An app can be used on a mobile phone or tablet.
Study: NCT06433154

Intervention type: PROCEDURE
Intervention: Arthroscopic surgery
Description: Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
Study: NCT05274971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active dietary management and aerobic exercise training.
Description: Active dietary management and aerobic exercise training.
Study: NCT05175430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
Study: NCT06454279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Specific Training
Description: Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible
Study: NCT03541889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT imaging and TK1 blood measurements
Description: F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT imaging and TK1 blood measurements
Description: F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
Study: NCT06176690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C7R.CD30.CAR-EBVST cells
Description: The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
Study: NCT05724953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Awareness
Description: Intervention involving psychoeducation and daily emotion awareness practices
Study: NCT06251375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo will be given as continuous infusion.
Study: NCT04829682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT for Life
Description: ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
Study: NCT06433687

Intervention type: DEVICE
Intervention: HekaHeart platform medication management and remote monitoring
Description: Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
Study: NCT04763252

Intervention type: OTHER
Intervention: Spectrum Therapeutics cannabis products
Description: For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products.
Study: NCT06653803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid Intercostal Block (RIB)
Description: Intraoperative Ipsilateral Ultrasound-guided RIB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar Block (RLB)
Description: Intraoperative Ipsilateral Ultrasound-guided RLB
Study: NCT05117567

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Personal protection package
Description: A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
Study: NCT05073484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions
Study: NCT02077036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetic Oscillation Stimulation Device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinetic Oscillation Stimulation Device in placebo mode
Study: NCT06099808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback Emails
Description: Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback Emails
Description: Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Specific Targets
Description: Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Resources
Description: Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Resources
Description: Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Resources
Description: Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
Study: NCT06655363

Intervention type: OTHER
Intervention: Anatomical description
Description: Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.

Intervention type: OTHER
Intervention: Radiological (MRI) description
Description: Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
Study: NCT06237439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Move with HaRT
Description: Move with HaRT is a group-based, manualized mind-body intervention.
Study: NCT05653284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK130
Description: IV infusion, specified dose on specified days.
Study: NCT05010616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Description: Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships.